🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
276

Quick answer

Takeda has 276 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Soticlestat

    Takeda

    Healthy Volunteers

    phase 1 small molecule terminated

    4 trials

  2. Soticlestat

    Takeda

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  3. Soticlestat 300 mg

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  4. TAK-004

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  5. TAK-007

    Takeda

    Refractory Lupus Nephritis

    phase 1 mab terminated

    1 trial

  6. TAK-020

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  7. TAK-020 Captisol Oral Solution

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  8. TAK-058

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  9. TAK-058

    Takeda

    Schizophrenia

    phase 1 small molecule terminated

    1 trial

  10. TAK-058 (ENV8058)

    Takeda

    Dose Finding Study

    phase 1 small molecule completed

    1 trial

  11. TAK-063

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  12. TAK-063

    Takeda

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  13. TAK-071

    Takeda

    Alzheimer Disease

    phase 1 small molecule terminated

    1 trial

  14. TAK-079

    Takeda

    Autoimmune Disease

    phase 1 small molecule completed

    1 trial

  15. TAK-079

    Takeda

    Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  16. TAK-079

    Takeda

    Systemic Lupus Erythematosus

    phase 1 small molecule completed

    1 trial

  17. TAK-102

    Takeda

    Solid Tumors

    phase 1 mab terminated

    1 trial

  18. TAK-103

    Takeda

    Solid Tumors

    phase 1 mab terminated

    1 trial

  19. TAK-105-a

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  20. TAK-114 10 mg capsule

    Takeda

    Clinical Pharmacology

    phase 1 small molecule completed

    1 trial

  21. TAK-117

    Takeda

    Metastatic Solid Tumors

    phase 1 small molecule completed

    1 trial

  22. TAK-117

    Takeda

    Neoplasm, Advanced or Metastatic

    phase 1 small molecule completed

    1 trial

  23. TAK-123

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  24. TAK-137

    Takeda

    Attention-Deficit/Hyperactivity Disorder

    phase 1 small molecule terminated

    1 trial

  25. TAK-137

    Takeda

    Dose Finding Study

    phase 1 small molecule completed

    1 trial

  26. TAK-137 5 mg tablet, TAK-137 placebo tablet

    Takeda

    Healthy Japanese Adult Male

    phase 1 small molecule terminated

    1 trial

  27. TAK-164

    Takeda

    Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

    phase 1 small molecule terminated

    1 trial

  28. TAK-165

    Takeda

    Breast Neoplasm

    phase 1 small molecule completed

    1 trial

  29. TAK-227

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  30. TAK-228

    Takeda

    Advanced Nonhematologic Malignancies

    phase 1 small molecule completed

    1 trial

  31. TAK-233

    Takeda

    Clinical Pharmacology

    phase 1 small molecule completed

    1 trial

  32. TAK-272

    Takeda

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  33. TAK-272

    Takeda

    Japanese Healthy Adult Males

    phase 1 small molecule completed

    1 trial

  34. TAK-279

    Takeda

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  35. TAK-279

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    3 trials

  36. TAK-279

    Takeda

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  37. TAK-329

    Takeda

    Type 1 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  38. TAK-385

    Takeda

    Hormone Treatment-naïve Participants With Prostate Cancer

    phase 1 small molecule completed

    1 trial

  39. TAK-385 40 mg

    Takeda

    Japanese Premenopausal Healthy Adult Women

    phase 1 small molecule completed

    1 trial

  40. TAK-385 T2 Formulation

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  41. TAK-418

    Takeda

    Healthy Volunteers

    phase 1 small molecule terminated

    2 trials

  42. TAK-418

    Takeda

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  43. TAK-438

    Takeda

    Erosive Esophagitis(EE)

    phase 1 small molecule completed

    1 trial

  44. TAK-438

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  45. TAK-438

    Takeda

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  46. TAK-438

    Takeda

    Ascending Single Dose Study

    phase 1 small molecule completed

    1 trial

  47. TAK-438

    Takeda

    Dose Finding Study

    phase 1 small molecule completed

    2 trials

  48. TAK-438 OD

    Takeda

    Japanese Healthy Adult Male

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Takeda have?

276 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.